secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2023-01-30T23:59:59+00:00
Accession:  0001493152-23-002910
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma reports $28.8M cash, focuses LNC on nucleic acids, pauses MAT2203 Phase 3 for BARDA
--------------------------------------------------------------------------------

- Preliminary cash of $28.8M at Dec 31, 2022, down from $49.6M at Dec 31, 2021; runway projected into Q2 2024.
- LNC platform achieves intracellular delivery of larger nucleic acids, mRNA stable >10 weeks at 4°C, low cytotoxicity.
- MAT2203 Phase 3 for cryptococcal meningitis paused pending BARDA evaluation; FDA meeting planned Q2 2023 for second Phase 3 study in four invasive fungal infections (approx. 100 patients).
- BioNTech collaboration: in vivo studies start Q1 2023, data expected Q2 2023; Resilience initial data in Q2/Q3 2023; Genentech extended through 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223002910/0001493152-23-002910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223002910/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-002910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer